ROIV
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch \"Vants\" - nimble and focused biopharmaceutical and health technology companies
Roivant Sciences Ltd. (ROIV) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | F (0.1) | B- (2.9) | C (2.3) | B (3.5) | F (0.6) | C- (1.9) |
| 2026-11-09 | F (0.0) | D+ (1.6) | D+ (1.6) | B+ (3.5) | F (0.6) | D (1.5) |
| 2026-11-02 | F (0.0) | D+ (1.5) | D+ (1.7) | B+ (3.7) | F (0.6) | D (1.5) |
| 2026-10-30 | F (0.0) | D (1.2) | D+ (1.7) | B (3.4) | D+ (1.6) | D+ (1.6) |
| 2026-10-26 | F (0.0) | D (1.2) | D+ (1.7) | B (3.3) | C (2.4) | D+ (1.7) |